Today: 20 May 2026
Amazon Stock Rises on AWS AI Growth — Why AMZN’s Cloud Beat Matters Now

Amazon Stock Rises on AWS AI Growth — Why AMZN’s Cloud Beat Matters Now

Seattle, April 30, 2026, 04:01 (PDT)

  • Amazon Web Services just delivered its quickest sales growth in 15 quarters, helping to calm investor nerves around the company’s aggressive AI spending spree.
  • Amazon projected second-quarter revenue ahead of Wall Street targets, factoring in an expected Prime Day during the period.
  • Cash outflows remain a concern—AI spending continues to hit free cash flow, even as Google Cloud posts stronger growth.

Amazon.com stock climbed in early trading Thursday, following a better-than-anticipated performance from Amazon Web Services. The company’s cloud unit delivered solid growth, hinting that demand from businesses for AI infrastructure is beginning to make a meaningful impact on sales. Shares recently changed hands at $263.04, up roughly 1.4% from the previous close.

That’s become crucial with Amazon under pressure to show its massive outlays on data centers, custom chips, and AI products can deliver a payoff that justifies the spending. CEO Andy Jassy has stuck with the company’s $200 billion capital spending plan for 2026, according to Reuters, as investors across Big Tech ramp up demands for clear AI gains.

Amazon posted a 17% jump in first-quarter net sales, hitting $181.5 billion. Revenue from AWS surged 28% to $37.6 billion. Operating income reached $23.9 billion, up from $18.4 billion last year. Net income landed at $30.3 billion, boosted by $16.8 billion in pre-tax gains related to Amazon’s Anthropic investment.

“AWS is growing 28%,” Jassy said in Amazon’s earnings statement, highlighting it as the cloud group’s quickest growth in 15 quarters. He mentioned as well that Amazon’s chips segment hit an annual revenue run rate north of $20 billion—a rough estimate that simply projects the unit’s current quarterly sales pace across an entire year. Amazon

Amazon is forecasting revenue between $194 billion and $199 billion for the current quarter, translating to growth of 16% to 19%. Operating income guidance landed between $20 billion and $24 billion. The company noted this outlook factors in Prime Day taking place during the second quarter.

Cloud performance grabbed analyst attention. “The significant reacceleration in AWS sales growth is the standout story,” Jesse Cohen, senior analyst at Investing.com, told Reuters. According to Cohen, Amazon customers are bringing in new AI workloads. Reuters

The picture for competitors was muddier. Google Cloud, part of Alphabet, posted a 63% jump to $20 billion for the quarter, Reuters said. That’s a sharper rise than AWS managed, though Google’s cloud business is still smaller. “Much better growth rate” for Google Cloud, said D.A. Davidson’s Gil Luria to Reuters, might be “a slight disappointment” for AWS. Reuters

Amazon is shoring up its AI business. On April 28, OpenAI announced plans to bring its Codex coding agent and managed agents to AWS. Amazon responded, confirming those tools would be available via Bedrock, its AI model management platform.

The company is putting more weight behind Anthropic, the creator of Claude AI models. According to Reuters, Amazon has agreed to invest as much as $25 billion in Anthropic, which in turn is set to pour more than $100 billion over a decade into Amazon’s cloud services.

Retail pitched in, and advertising gave a strong boost. North America sales jumped 12% to $104.1 billion, while international sales climbed 19%, ending up at $39.8 billion. Advertising services pulled in $17.24 billion—an increase of 24%. Amazon counts sales of sponsored ads, video and display ads, plus similar programs for sellers, vendors, publishers, and others as advertising services.

Still, that’s a hefty bill. Amazon’s free cash flow landed at $1.2 billion for the trailing 12 months, a steep drop from $25.9 billion a year ago, according to the company. First-quarter capital expenditures hit $44.2 billion, topping what analysts had expected, Reuters noted.

The next hurdle: Can AWS maintain this momentum as Amazon invests in capacity before it’s needed? Rapid cloud gains give Jassy breathing room, but investors aren’t letting go of one question—once these AI factories are up and running, just how much cash will they generate?

Stock Market Today

  • Roivant Sciences Q4 Loss Beats Estimates; Revenue Misses
    May 20, 2026, 9:59 AM EDT. Roivant Sciences Ltd. reported a fourth-quarter loss of $0.23 per share, better than the Zacks estimate of a $0.25 loss, marking an 8% positive earnings surprise. Revenue missed expectations, coming in at $28.93 million, down 11% from estimates but up from $27.38 million a year ago. Despite three out of four quarters beating EPS estimates recently, the company's shares have declined 4.5% year-to-date, underperforming the S&P 500's 10.4% rise. Earnings outlook remains cautious with a Zacks Rank #4 (Sell), suggesting expected near-term underperformance. Current consensus projects a loss of $0.21 per share next quarter on $56.64 million revenue and a fiscal year loss of $1.07 on $172.45 million. Industry outlook in medical-biomedical genetics also weighs on investor sentiment.

Latest articles

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

Vida CEO Steps In as $15 Million AI IPO Hits Reality Check

20 May 2026
Vida Global Inc. raised $15 million in its May 18 IPO, selling 3.75 million shares at $4 each, but the stock closed at $2.29 on Tuesday. CEO Lyle Pratt bought 312,900 shares for about $1.19 million, according to a Form 4 filing. Vida reported 2025 revenue of $551,383 and a net loss of $2.9 million. The company’s shares trade on NYSE American and NYSE Texas under the symbol VIDA.
TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

TJX Shares Rise Premarket As T.J. Maxx Parent Raises Outlook

20 May 2026
TJX raised its fiscal 2027 sales, earnings, and buyback targets after first-quarter comparable sales rose 6% and net income hit $1.3 billion. Shares climbed 3.6% in premarket trading. The company cited higher fuel costs as a drag on its full-year forecast. Marmaxx, HomeGoods, and TJX Canada all posted strong sales growth.
ImmunityBio in the Spotlight with Patents and BCG Deal Ahead of the Open

ImmunityBio Faces FDA Decision on Bladder-Cancer Application, Risk Remains

20 May 2026
The FDA accepted ImmunityBio’s application to expand Anktiva’s use with BCG in papillary-only, BCG-unresponsive non-muscle invasive bladder cancer, setting a Jan. 6, 2027 decision date. ImmunityBio reported $44.2 million in first-quarter net product revenue and held $380.9 million in cash and equivalents. Shares last traded at $7.76, down 2.8%. The filing is supported by data from 80 patients in a Phase 2/3 trial.
Why Intel Stock Hit a Record: Google AI Chip Report Puts Foundry Turnaround in Focus
Previous Story

Why Intel Stock Hit a Record: Google AI Chip Report Puts Foundry Turnaround in Focus

Caterpillar Earnings Beat: AI Data Center Power Demand Drives a Q1 Surprise for CAT Stock
Next Story

Caterpillar Earnings Beat: AI Data Center Power Demand Drives a Q1 Surprise for CAT Stock

Go toTop